References
- Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an orphan disease to a public health problem. Chest. 2007;132(2):365–67.doi:https://doi.org/10.1378/chest.07-0903.
- Voelkel N, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40(6):1555–65.doi:https://doi.org/10.1183/09031936.00046612.
- Rosenzweig E, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019;53:1.
- Watts SW, Priestley JR, Thompson JM, Kreindler JL. Serotonylation of vascular proteins important to contraction. PLoS One. 2009;4(5):e5682. doi:https://doi.org/10.1371/journal.pone.0005682.
- DiRaimondo TR, Klöck C, Warburton R, Herrera Z, Penumatsa K, Toksoz D, Hill N, Khosla C, Fanburg B. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice. ACS Chem Biol. 2014;9(1):266–75.doi:https://doi.org/10.1021/cb4006408.
- Penumatsa K, Toksoz D, Warburton RR, Kharnaf M, Preston IR, Kapur NK, Khosla C, Hill NS, Fanburg BL. Transglutaminase 2 in pulmonary and cardiac tissue remodeling in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313(5):L752–L762.doi:https://doi.org/10.1152/ajplung.00170.2017.
- Penumatsa KC, Fanburg BL. Transglutaminase 2-mediated serotonylation in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;306(4):L309–15. doi:https://doi.org/10.1152/ajplung.00321.2013.
- Jiang S, Wang Y-H, Hu L-P, Wang X, Li J, Zhang X-L, Zhang Z-G. The physiology, pathology and potential therapeutic application of serotonylation. J Cell Sci. 2021;134:11.
- Zhu Z, Wang Y, Long A, Feng T, Ocampo M, Chen S, Tang H, Guo Q, Minshall R, Makino A, et al. Pulmonary vessel casting in a rat model of monocrotaline-mediated pulmonary hypertension. Pulm Circ. 2020;10(3):2045894020922129.doi:https://doi.org/10.1177/2045894020922129.
- Zhao J, Yang M, Wu X, Yang Z, Jia P, Sun Y, Li G, Xie L, Liu B, Liu H, et al. Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension. Exp Ther Med. 2019;17(2):1163–70.doi:https://doi.org/10.3892/etm.2018.7045.
- Qiu JF, Zhang ZQ, Chen W, Wu ZY. Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol. 2007;13(32):4328–32.doi:https://doi.org/10.3748/wjg.v13.i32.4328.
- Sakao S, Tatsumi K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int J Cardiol. 2011;147(1):4–12. doi:https://doi.org/10.1016/j.ijcard.2010.07.003.
- Adnot S, Houssaini A, Abid S, Marcos E, Amsellem V. Serotonin transporter and serotonin receptors. Handb Exp Pharmacol. 2013;218:365–80.
- Gu J, Zhang H, Ji B, Jiang H, Zhao T, Jiang R, Zhang Z, Tan S, Ahmed A, Gu Y, et al. Vesicle miR-195 derived from endothelial cells inhibits expression of serotonin transporter in vessel smooth muscle cells. Sci Rep. 2017;7:43546.
- Marcos E, Fadel E, Sanchez O, Humbert M, Dartevelle P, Simonneau G, Hamon M, Adnot S, Eddahibi S. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res. 2004;94(9):1263–70.doi:https://doi.org/10.1161/01.RES.0000126847.27660.69.
- Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108(8):1141–50. doi:https://doi.org/10.1172/JCI200112805.
- Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301(2):H287–96. doi:https://doi.org/10.1152/ajpheart.00327.2011.
- Montagnoli T, Da Silva JS, Sudo SZ, Santos AD, Gomide GF, de Sá MPL, Zapata-Sudo G. ROCK inhibition as potential target for treatment of pulmonary hypertension. Cells. 2021;10:7.
- Gien J, Seedorf GJ, Balasubramaniam V, Tseng N, Markham N, Abman SH. Chronic intrauterine pulmonary hypertension increases endothelial cell Rho kinase activity and impairs angiogenesis in vitro. Am J Physiol Lung Cell Mol Physiol. 2008;295(4):L680–7.doi:https://doi.org/10.1152/ajplung.00516.2007.
- Li FH, Wei XI, Li AW, Zhao CF, Sun RP. Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. Chin Med J (Engl). 2007;120(1):22–29.doi:https://doi.org/10.1097/00029330-200701010-00005.
- Wang N, Guan P, Zhang J-P, Li Y-Q, Chang Y-Z, Shi Z-H, Wang F-Y, Chu L. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways. J Cell Biochem. 2011;112(7):1920–29.doi:https://doi.org/10.1002/jcb.23112.
- Nurminskaya MV, Belkin AM. Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol. 2012;294:1–97. doi:https://doi.org/10.1016/B978-0-12-394305-7.00001-X.
- Pinilla E, Comerma-Steffensen S, Prat-Duran J, Rivera L, Matchkov VV, Buus NH, Simonsen U. Transglutaminase 2 inhibitor LDN 27219 age-dependently lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries. Hypertension (Dallas, Tex: 1979). 2021;77(1):216–27.doi:https://doi.org/10.1161/HYPERTENSIONAHA.120.15352.
- Bader M. Serotonylation: serotonin signaling and epigenetics. Front Mol Neurosci. 2019;12:288. doi:https://doi.org/10.3389/fnmol.2019.00288.
- Guilluy C, Rolli-Derkinderen M, Tharaux PL, Melino G, Pacaud P, Loirand G. Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem. 2007;282(5):2918–28.doi:https://doi.org/10.1074/jbc.M604195200.
- Guilluy C, Eddahibi S, Agard C, Guignabert C, Izikki M, Tu L, Savale L, Humbert M, Fadel E, Adnot S, Loirand G. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009;179(12):1151–58. doi:https://doi.org/10.1164/rccm.200805-691OC.
- Keillor JW, Apperley KY, Akbar A. Inhibitors of tissue transglutaminase. Trends Pharmacol Sci. 2015;36(1):32–40. doi:https://doi.org/10.1016/j.tips.2014.10.014.
- Jeitner TM, Delikatny EJ, Ahlqvist J, Capper H, Cooper AJL. Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol. 2005;69(6):961–70.doi:https://doi.org/10.1016/j.bcp.2004.12.011.
- Suh IB, Yoon DW. Effects of transglutaminase 2 inhibition on ventilator-induced lung injury. J Korean Med Sci. 2014;29(4): 556–63. doi:https://doi.org/10.3346/jkms.2014.29.4.556. Epub 2014 Apr 1.
- Wang H, Liu W-Z, Tang F-T, Sui H-J, Zhan X-J, Wang H-X. Cystamine slows but not inverses the progression of monocrotaline-induced pulmonary arterial hypertension in rats. Can J Physiol Pharmacol. 2018;96(8):783–89.doi:https://doi.org/10.1139/cjpp-2017-0720.
- Liu Y, Wei L, Laskin DL, Fanburg BL. Role of protein transamidation in serotonin-induced proliferation and migration of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2011;44(4):548–55.doi:https://doi.org/10.1165/rcmb.2010-0078OC.
- Wang HM, Wang Y, Liu M, Bai Y, Zhang X-H, Sun Y-X, Wang H-L. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats. Can J Physiol Pharmacol. 2012;90(11): pp. 1506–15.doi:https://doi.org/10.1139/y2012-108.